On-Demand Content | Virtual Event
AGENDA – ALL TIMES ARE IN EASTERN TIME
Speakers will be available for Q&A and further dialogue within their respective ‘Meet The Speaker’ Break Out Roundtables: A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
Paul Fehlner
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
- Discussion on how to facilitate global sharing in a fair way
- Effective trust mechanism development without undermining IP laws.
- Leveraging capability of information. Information gained and shared would be impossible for one company to accomplish alone
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
- Policies and best practices for deals with local and global companies or possible partners
- How to protect your information and the information most important to your partners while partnering digitally
- How anti-bribery initiatives make investments and transactions most effective
Due Diligence Specialist and Third Party Risk Management Champion
NOVARTIS
- How to know who you are dealing with and establish trust on both sides early on
- Best practices when establishing data integrity while remaining compliant
- Global standardization and digital era changing the landscape of compliance and due diligence
Vice President, Medical and Regulatory Affairs
NEOPHARM GROUP COMPANIES
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
Paul Fehlner
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
Sabeena Ghazal
Due Diligence Specialist and Third Party Risk Management Champion
NOVARTIS
Dr. Segev Shani
Vice President, Medical and Regulatory Affairs
NEOPHARM GROUP COMPANIES
Paul Fehlner
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
Sabeena Ghazal
Due Diligence Specialist and Third Party Risk Management Champion
NOVARTIS
Dr. Segev Shani
Vice President, Medical and Regulatory Affairs
NEOPHARM GROUP COMPANIES
- Most due diligence conversation is based on what happens before an agreement is reached, but due diligence after an agreement is reached is just as important to the deal and companies involved
- Creating meaningful value for the company on either side of the agreement
- Working to maintain trust and how to avoid losses from lack of post-due diligence
Advisor, External Innovation – Due Diligence
ELI LILLY
- How information is collected from a diligence to apply to M&A to be most effective and helpful in the process
- Discussion of the wide scope of the diligence and information needed when acquiring a company (people, real-estate, infrastructure, etc)
- Navigating how to operate moving forward when an acquisition is made
Director of Alliance management and M&A Integration
ELI LILLY
- Explore the collaboration tools and techniques that are used and evolved over the years
- Define the similarities and differences of cross functional and cross business collaboration
- Accelerate planning and execution to leverage collaboration through adjusting and creating timelines
Head, Corporate Development
CARE EVERYWHERE GROUP
A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
Scott Simmons
Advisor, External Innovation – Due Diligence
ELI LILLY
Steven Walker
Director of Alliance management and M&A Integration
ELI LILLY
Samuel Gosselin
Head, Corporate Development
CARE EVERYWHERE GROUP
Scott Simmons
Advisor, External Innovation – Due Diligence
ELI LILLY
Steven Walker
Director of Alliance management and M&A Integration
ELI LILLY
Samuel Gosselin
Head, Corporate Development
CARE EVERYWHERE GROUP
Speakers will be available for Q&A and further dialogue within their respective ‘Meet The Speaker’ Break Out Roundtables: A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
- Use diligence to showcase corporate excellence — buyers already love your IP or don’t care about it.
- Demonstrate that you handle the IP ministerial paperwork perfectly — otherwise buyers may wonder what other problems lurk in the rest of the business.
- Do what you can to reassure buyers that they aren’t walking into an IP dispute
M.D./Ph.D. Patent Consultant and Former Administrative Patent Judge
INDEPENDENT CONSULTANT
- Cross-functional information flow, internally and externally, within the organization during a due diligence
- Discussing how to navigate the challenge of drawing conclusions while information is incomplete
- How to advise the business at times of legal uncertainty and protecting from contamination issues of all programs
Mehdi Ganjeizadeh, Ph.D., J.D.
Executive Director and Head of Gene Therapy IP
SAREPTA THERAPEUTICS
Stephan Kutik
IP Lead for Nephrology and Orphan Drugs
VIFOR PHARMA
Lindsey Wanner
Senior Counsel, IP Alliance and Due Diligence
GILEAD SCIENCES
- How the legislative changes in congress are affecting pharmaceutical patents
- The nuances of PTAB self-legislating in this developing landscape
- Perspectives on different patent provisions
M.D./Ph.D. Patent Consultant and Former Administrative Patent Judge
INDEPENDENT CONSULTANT
David Korn
Vice President of Intellectual Property and Law
PHRMA
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
Scott Kamholz
M.D./Ph.D. Patent Consultant and Former Administrative Patent Judge
INDEPENDENT CONSULTANT
Stephan Kutik
IP Lead for Nephrology and Orphan Drugs
VIFOR PHARMA
Mehdi Ganjeizadeh, Ph.D., J.D.
Executive Director and Head of Gene Therapy IP
SAREPTA THERAPEUTICS
Lindsey Wanner
Senior Counsel, IP Alliance and Due Diligence
GILEAD SCIENCES
David Korn
Vice President of Intellectual Property and Law
PHRMA
Scott Kamholz
M.D./Ph.D. Patent Consultant and Former Administrative Patent Judge
INDEPENDENT CONSULTANT
Stephan Kutik
IP Lead for Nephrology and Orphan Drugs
VIFOR PHARMA
Mehdi Ganjeizadeh, Ph.D., J.D.
Executive Director and Head of Gene Therapy IP
SAREPTA THERAPEUTICS
Lindsey Wanner
Senior Counsel, IP Alliance and Due Diligence
GILEAD SCIENCES
David Korn
Vice President of Intellectual Property and Law
PHRMA
- Using specific due diligence steps to make the best investment or partnership for your organization
- Internal and external analysis focusing on key issues and possible red flags on either side of the deal
- External analysis and understanding of the capital and cash flow of each organization- including any possible or pending M&A
Ahmed Mousa
Chief Business Officer, General Counsel
PIERIS PHARMACEUTICALS
Christopher Mortko
Associate Vice President and Head of Search and Evaluation in Business Development and Licensing
MERCK
Ravi Kiron
Head of BioPharma External Innovation
EMD SERONO, INC.
Gwilym Attwell
Patent Attorney
FISH & RICHARDSON
- Quick processes that are cost effective and leverage partners
- Insight into regulatory IIS practices
- Why cell therapy is so ahead in China and how partnering with these companies can help develop the global market
Global Head Search, Evaluation Oncology
SIMCERE PHARMACEUTICAL GROUP
Paul Fehlner
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
Senior Vice President, Chief Legal Officer and Corporate Secretary
AXCELLA
Allow for the movement into smaller groups of your industry peers based upon the respective topics, and aligning your shared interests/expertise. A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speaker, but also with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts. The speaker may have questions for you!
Ahmed Mousa
Chief Business Officer, General Counsel
PIERIS PHARMACEUTICALS
Christopher Mortko
Associate Vice President and Head of Search and Evaluation in Business Development and Licensing
MERCK
Ravi Kiron
Head of BioPharma External Innovation
EMD SERONO, INC.
Gwilym Attwell
Patent Attorney
FISH & RICHARDSON
Markus Decker
Global Head Search, Evaluation Oncology
SIMCERE PHARMACEUTICAL GROUP
Ahmed Mousa
Chief Business Officer, General Counsel
PIERIS PHARMACEUTICALS
Christopher Mortko
Associate Vice President and Head of Search and Evaluation in Business Development and Licensing
MERCK
Ravi Kiron
Head of BioPharma External Innovation
EMD SERONO, INC.
Gwilym Attwell
Patent Attorney
FISH & RICHARDSON
Markus Decker
Global Head Search, Evaluation Oncology
SIMCERE PHARMACEUTICAL GROUP